U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H24FN3O4.ClH
Molecular Weight 437.892
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MOXIFLOXACIN HYDROCHLORIDE

SMILES

Cl.[H][C@]12CN(C[C@@]1([H])NCCC2)C3=C(OC)C4=C(C=C3F)C(=O)C(=CN4C5CC5)C(O)=O

InChI

InChIKey=IDIIJJHBXUESQI-DFIJPDEKSA-N
InChI=1S/C21H24FN3O4.ClH/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24;/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28);1H/t11-,16+;/m0./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C21H24FN3O4
Molecular Weight 401.4314
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16337789 | https://www.ncbi.nlm.nih.gov/pubmed/20516287 | https://www.ncbi.nlm.nih.gov/pubmed/25801151 | https://www.ncbi.nlm.nih.gov/pubmed/11600361

Moxifloxacin is a synthetic antibacterial agent developed by Bayer AG (initially called BAY 12-8039) for oral and intravenous administration. Moxifloxacin, a fluoroquinolone, is available as the monohydrochloride salt of 1-cyclopropyl-7-[(S,S)-2,8diazabicyclo[4.3.0]non-8-yl]-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3 quinoline carboxylic acid. Moxifloxacin is marketed worldwide (as the hydrochloride) under the brand names Avelox, Avalox, and Avalon for oral treatment. In most countries, the drug is also available in the parenteral form for intravenous infusion. Moxifloxacin is also sold in an ophthalmic solution (eye drops) under the brand names Vigamox, and Moxeza for the treatment of conjunctivitis (pink eye). Its antibacterial spectrum includes enteric Gram-(−) rods (Escherichia coli, Proteus species, Klebsiella species), Haemophilus influenzae, atypical bacteria (Mycoplasma, Chlamydia, Legionella), and Streptococcus pneumoniae, and anaerobic bacteria. It differs from earlier antibacterials of the fluoroquinolone class such as levofloxacin and ciprofloxacin in having greater activity against Gram-positive bacteria and anaerobes.

CNS Activity

Curator's Comment: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s061s062,021277s057s058lbl.pdf

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
800.0 nM [IC50]
9200.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
AVELOX

Approved Use

INDICATIONS AND USAGE AVELOX is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: Community Acquired Pneumonia, Skin and Skin Structure Infections: Uncomplicated and Complicated, Complicated Intra-Abdominal Infections, Plague, Acute Bacterial Sinusitis, Acute Bacterial Exacerbation of Chronic Bronchitis, To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs. AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Launch Date

1999
Curative
AVELOX

Approved Use

INDICATIONS AND USAGE AVELOX is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: Community Acquired Pneumonia, Skin and Skin Structure Infections: Uncomplicated and Complicated, Complicated Intra-Abdominal Infections, Plague, Acute Bacterial Sinusitis, Acute Bacterial Exacerbation of Chronic Bronchitis, To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs. AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Launch Date

1999
Curative
AVELOX

Approved Use

INDICATIONS AND USAGE AVELOX is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: Community Acquired Pneumonia, Skin and Skin Structure Infections: Uncomplicated and Complicated, Complicated Intra-Abdominal Infections, Plague, Acute Bacterial Sinusitis, Acute Bacterial Exacerbation of Chronic Bronchitis, To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs. AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Launch Date

1999
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.1 mg/L
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4.2 mg/L
400 mg 1 times / day multiple, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
3.9 mg/L
400 mg single, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4.5 mg/L
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
443.07 ng/ml
1 drop 4 times / day multiple, ocular
dose: 1 drop
route of administration: ocular
experiment type: multiple
co-administered:
MOXIFLOXACIN aqueous humor
Homo sapiens
population: unhealthy
age:
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
36.1 mg × h/L
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
38 mg × h/L
400 mg 1 times / day multiple, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
39.3 mg × h/L
400 mg single, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
48 mg × h/L
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
13.55 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
14.8 h
400 mg 1 times / day multiple, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
11.8 h
400 mg single, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
12.7 h
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
60%
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
60%
400 mg single, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
600 mg 1 times / day multiple, oral
Higher than recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources: Page: p.5
healthy, 30±7
n = 7
Health Status: healthy
Age Group: 30±7
Sex: M
Population Size: 7
Sources: Page: p.5
800 mg single, oral
Highest studied dose
Dose: 800 mg
Route: oral
Route: single
Dose: 800 mg
Sources: Page: p.2062
healthy, 33.6
n = 8
Health Status: healthy
Age Group: 33.6
Sex: M
Population Size: 8
Sources: Page: p.2062
400 mg 1 times / day multiple, intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.8.9
unhealthy, 50
Health Status: unhealthy
Condition: Bacterial infections
Age Group: 50
Sex: M+F
Sources: Page: p.8.9
Disc. AE: Rash...
AEs leading to
discontinuation/dose reduction:
Rash
Sources: Page: p.8.9
400 mg 1 times / day multiple, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.8.9
unhealthy, 50
Health Status: unhealthy
Condition: Bacterial infections
Age Group: 50
Sex: M+F
Sources: Page: p.8.9
Disc. AE: Nausea, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Nausea (>0.3)
Diarrhea (>0.3)
Dizziness (>0.3)
Vomiting (>0.3)
Sources: Page: p.8.9
800 mg 1 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.7
unhealthy, 57.8
n = 5
Health Status: unhealthy
Condition: Chronic bronchitis
Age Group: 57.8
Sex: M+F
Population Size: 5
Sources: Page: p.7
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Co-administed with::
Linezolid, IV(600 mg q12h)
Sources: Page: p.1863
unhealthy, 59.6
n = 273
Health Status: unhealthy
Condition: Community-acquired bacterial pneumonia
Age Group: 59.6
Sex: M+F
Population Size: 273
Sources: Page: p.1863
Disc. AE: Erythema, QT interval prolonged...
AEs leading to
discontinuation/dose reduction:
Erythema (0.37%)
QT interval prolonged (1%)
Angioedema (serious, 0.37%)
Sources: Page: p.1863
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Bacterial infections
Sources: Page: p.1
Disc. AE: Tendinitis, Tendon rupture...
AEs leading to
discontinuation/dose reduction:
Tendinitis
Tendon rupture
Peripheral neuropathy
Central nervous system disorder NOS
Myasthenia gravis
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Rash Disc. AE
400 mg 1 times / day multiple, intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.8.9
unhealthy, 50
Health Status: unhealthy
Condition: Bacterial infections
Age Group: 50
Sex: M+F
Sources: Page: p.8.9
Diarrhea >0.3
Disc. AE
400 mg 1 times / day multiple, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.8.9
unhealthy, 50
Health Status: unhealthy
Condition: Bacterial infections
Age Group: 50
Sex: M+F
Sources: Page: p.8.9
Dizziness >0.3
Disc. AE
400 mg 1 times / day multiple, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.8.9
unhealthy, 50
Health Status: unhealthy
Condition: Bacterial infections
Age Group: 50
Sex: M+F
Sources: Page: p.8.9
Nausea >0.3
Disc. AE
400 mg 1 times / day multiple, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.8.9
unhealthy, 50
Health Status: unhealthy
Condition: Bacterial infections
Age Group: 50
Sex: M+F
Sources: Page: p.8.9
Vomiting >0.3
Disc. AE
400 mg 1 times / day multiple, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.8.9
unhealthy, 50
Health Status: unhealthy
Condition: Bacterial infections
Age Group: 50
Sex: M+F
Sources: Page: p.8.9
Erythema 0.37%
Disc. AE
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Co-administed with::
Linezolid, IV(600 mg q12h)
Sources: Page: p.1863
unhealthy, 59.6
n = 273
Health Status: unhealthy
Condition: Community-acquired bacterial pneumonia
Age Group: 59.6
Sex: M+F
Population Size: 273
Sources: Page: p.1863
QT interval prolonged 1%
Disc. AE
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Co-administed with::
Linezolid, IV(600 mg q12h)
Sources: Page: p.1863
unhealthy, 59.6
n = 273
Health Status: unhealthy
Condition: Community-acquired bacterial pneumonia
Age Group: 59.6
Sex: M+F
Population Size: 273
Sources: Page: p.1863
Angioedema serious, 0.37%
Disc. AE
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Co-administed with::
Linezolid, IV(600 mg q12h)
Sources: Page: p.1863
unhealthy, 59.6
n = 273
Health Status: unhealthy
Condition: Community-acquired bacterial pneumonia
Age Group: 59.6
Sex: M+F
Population Size: 273
Sources: Page: p.1863
Central nervous system disorder NOS Disc. AE
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Bacterial infections
Sources: Page: p.1
Myasthenia gravis Disc. AE
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Bacterial infections
Sources: Page: p.1
Peripheral neuropathy Disc. AE
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Bacterial infections
Sources: Page: p.1
Tendinitis Disc. AE
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Bacterial infections
Sources: Page: p.1
Tendon rupture Disc. AE
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Bacterial infections
Sources: Page: p.1
PubMed

PubMed

TitleDatePubMed
In vitro susceptibility and eradication of Chlamydia pneumoniae cardiovascular strains from coronary artery endothelium and smooth muscle cells.
2001
Streptococcus pneumoniae as an agent of nosocomial infection: treatment in the era of penicillin-resistant strains.
2001
Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint.
2001
Comparison of side effects of levofloxacin versus other fluoroquinolones.
2001
Effect of probenecid on the kinetics of a single oral 400mg dose of moxifloxacin in healthy male volunteers.
2001
Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline.
2001
Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans.
2001
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
2001 Apr
Fluoroquinolone susceptibility, resistance, and pharmacodynamics versus clinical isolates of Streptococcus pneumoniae from Indiana.
2001 Aug
Treatment of Staphylococcus aureus endocarditis using moxifloxacin.
2001 Aug
In vitro activity of fosfomycin in combination with various antistaphylococcal substances.
2001 Aug
The inhibition and selectivity of bacterial topoisomerases by BMS-284756 and its analogues.
2001 Aug
A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae.
2001 Aug 15
Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
2001 Jul
Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp.
2001 Jul
The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia.
2001 Jul
The use of fluoroquinolones as antiinfective transition-therapy agents in community-acquired pneumonia.
2001 Jul
Comparative in vitro study of the activity of moxifloxacin and other antibiotics against 150 strains of penicillin non-susceptible Streptococcus pneumoniae and against 110 strains of ampicillin-resistant Haemophilus influenzae isolated in 1999-2000 in Spain.
2001 Jul
[Hypertensive crisis and transitory left brunch block with QT interval prolongation associated to moxifloxacin].
2001 Jul 7
A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis.
2001 Jul-Aug
Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience.
2001 Jun
Microbial drug resistance and the roles of the new antibiotics.
2001 Jun
A comparison of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model.
2001 Jun
Conventional dogma applied to quinolones? Time for a change.
2001 Jun
Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.
2001 Jun
Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.
2001 Jun
Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective.
2001 Mar-Apr
Moxifloxacin in acute exacerbations of chronic bronchitis: clinical evaluation and assessment by patients.
2001 Mar-Apr
Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin.
2001 Mar-Apr
Chronic obstructive pulmonary disease.
2001 Mar-Apr
Immunomodulatory effects of moxifloxacin in comparison to ciprofloxacin and G-CSF in a murine model of cyclophosphamide-induced leukopenia.
2001 May
In vitro activity of ABT-773 versus macrolides and quinolones against resistant respiratory tract pathogens.
2001 May-Jun
Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.
2001 Nov
Comparison of antimicrobial in vitro activities against Streptococcus pneumoniae independent of MIC susceptibility breakpoints using MIC frequency distribution curves, scattergrams and linear regression analyses.
2001 Nov
[Diagnosis and therapy of abscess forming pneumonia].
2001 Oct
Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
2001 Oct
Clinical isolates of Streptococcus pneumoniae resistant to levofloxacin contain mutations in both gyrA and parC genes.
2001 Oct
Pharmacokinetics and pharmacodynamics of fluoroquinolones.
2001 Oct
Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia.
2001 Oct
Moxifloxacin does increase the corrected QT interval.
2001 Oct 15
In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
2001 Sep
The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis: a Spanish physician and patient experience.
2001 Sep
Is more than one quinolone needed in clinical practice?
2001 Sep
Future of the quinolones.
2001 Sep
Comparison of the in vitro activities of BMS-284756 and four fluoroquinolones against Streptococcus pneumoniae.
2001 Sep
Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolone exposure.
2001 Sep
Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
2001 Sep
Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.
2001 Sep 15
In vitro susceptibility study of BMS-284756 against Legionella species.
2001 Sep-Oct
In vitro activity of novel fluoroquinolones against Streptococcus pneumoniae isolated from children with acute otitis media.
2001 Sep-Oct
Patents

Sample Use Guides

The dose of AVELOX is 400 mg (orally or as an intravenous infusion) once every 24 hours. The duration of therapy depends on the type of infection (5--21 days).
Route of Administration: Oral
In Vitro Use Guide
Phagocytosed bacteria were divided into four aliquots with different concentrations of the drug (0, 0.1, 1 and 10 MIC). At baseline and after 1, 2 and 4 h incubation, the number of viable bacteria was determined by a subculture technique. Moxifloxacin was active against all tested staphylococci with MICs of 0.063–2 mg/L.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:45:36 GMT 2023
Edited
by admin
on Fri Dec 15 15:45:36 GMT 2023
Record UNII
C53598599T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MOXIFLOXACIN HYDROCHLORIDE
EP   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   WHO-DD  
USAN  
Official Name English
AL-15469A
Code English
MOXIFLOXACIN HYDROCHLORIDE [ORANGE BOOK]
Common Name English
BAY-12-8039
Code English
MOXIFLOXACIN HYDROCHLORIDE [USAN]
Common Name English
(4AS-CIS)-1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-8-METHOXY-7-(OCTAHYDRO-6H-PYRROLOL(3,4-B)PYRIDIN-6-YL)-4-OXO-3-QUINOLINECARBOXYLIC ACID, MONOHYDROCHLORIDE
Common Name English
MOXIFLOXACIN HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
MOXIFLOXACIN HYDROCHLORIDE [MI]
Common Name English
AVELOX
Brand Name English
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid, monohydrochloride
Common Name English
BAY 12-8039
Code English
MOXIFLOXACIN HYDROCHLORIDE [JAN]
Common Name English
MOXIFLOXACIN HYDROCHLORIDE [USP-RS]
Common Name English
VIGAMOX
Brand Name English
MOXIFLOXACIN HYDROCHLORIDE [MART.]
Common Name English
Moxifloxacin hydrochloride [WHO-DD]
Common Name English
MOXIFLOXACIN HCL
VANDF  
Common Name English
MOXIFLOXACIN HCL [VANDF]
Common Name English
MOXIFLOXACIN (AS HYDROCHLORIDE)
Common Name English
NSC-758875
Code English
MOXIFLOXACIN HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 428014
Created by admin on Fri Dec 15 15:45:36 GMT 2023 , Edited by admin on Fri Dec 15 15:45:36 GMT 2023
NCI_THESAURUS C795
Created by admin on Fri Dec 15 15:45:36 GMT 2023 , Edited by admin on Fri Dec 15 15:45:36 GMT 2023
Code System Code Type Description
CAS
186826-86-8
Created by admin on Fri Dec 15 15:45:36 GMT 2023 , Edited by admin on Fri Dec 15 15:45:36 GMT 2023
PRIMARY
FDA UNII
C53598599T
Created by admin on Fri Dec 15 15:45:36 GMT 2023 , Edited by admin on Fri Dec 15 15:45:36 GMT 2023
PRIMARY
SMS_ID
100000089652
Created by admin on Fri Dec 15 15:45:36 GMT 2023 , Edited by admin on Fri Dec 15 15:45:36 GMT 2023
PRIMARY
USAN
KK-69
Created by admin on Fri Dec 15 15:45:36 GMT 2023 , Edited by admin on Fri Dec 15 15:45:36 GMT 2023
PRIMARY
EVMPD
SUB03342MIG
Created by admin on Fri Dec 15 15:45:36 GMT 2023 , Edited by admin on Fri Dec 15 15:45:36 GMT 2023
PRIMARY
DRUG BANK
DBSALT000387
Created by admin on Fri Dec 15 15:45:36 GMT 2023 , Edited by admin on Fri Dec 15 15:45:36 GMT 2023
PRIMARY
EPA CompTox
DTXSID4045921
Created by admin on Fri Dec 15 15:45:36 GMT 2023 , Edited by admin on Fri Dec 15 15:45:36 GMT 2023
PRIMARY
RXCUI
228750
Created by admin on Fri Dec 15 15:45:36 GMT 2023 , Edited by admin on Fri Dec 15 15:45:36 GMT 2023
PRIMARY RxNorm
MERCK INDEX
m7647
Created by admin on Fri Dec 15 15:45:36 GMT 2023 , Edited by admin on Fri Dec 15 15:45:36 GMT 2023
PRIMARY Merck Index
RS_ITEM_NUM
1448606
Created by admin on Fri Dec 15 15:45:36 GMT 2023 , Edited by admin on Fri Dec 15 15:45:36 GMT 2023
PRIMARY
ChEMBL
CHEMBL32
Created by admin on Fri Dec 15 15:45:36 GMT 2023 , Edited by admin on Fri Dec 15 15:45:36 GMT 2023
PRIMARY
PUBCHEM
101526
Created by admin on Fri Dec 15 15:45:36 GMT 2023 , Edited by admin on Fri Dec 15 15:45:36 GMT 2023
PRIMARY
CHEBI
7008
Created by admin on Fri Dec 15 15:45:36 GMT 2023 , Edited by admin on Fri Dec 15 15:45:36 GMT 2023
PRIMARY
DAILYMED
C53598599T
Created by admin on Fri Dec 15 15:45:36 GMT 2023 , Edited by admin on Fri Dec 15 15:45:36 GMT 2023
PRIMARY
NSC
758875
Created by admin on Fri Dec 15 15:45:36 GMT 2023 , Edited by admin on Fri Dec 15 15:45:36 GMT 2023
PRIMARY
NCI_THESAURUS
C38696
Created by admin on Fri Dec 15 15:45:36 GMT 2023 , Edited by admin on Fri Dec 15 15:45:36 GMT 2023
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
SOLVATE->ANHYDROUS
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 3.5
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY